The invention relates to a compound of general formula : (I) wherein A is selected from the groups (a) (b) or (c): formula (II) or formula (III) (b) or is cycloalkyl (c) optionally substituted by lower alkyl (c)Ar is phenyl or a six membered heteroarylX is N or CH X is N R or O R is S(O) lower alkyl C(O) cycloalkyl substituted by lower alkyl or is C(O) lower alkyl lower alkyl cyano cycloalkyl or is a six membered heteroaryl substituted by lower alkyl cyano C(O) lower alkyl halogen lower alkyl substituted by halogen or lower alkoxy or is phenyl substituted by cyano or halogen R is lower alkyl halogen pyrazolyl 3 methyl [1 2 4]oxazolyl 5 methyl [1 2 4]oxadiazol 3 yl pyridyl substituted by cyano or is phenyl substituted by halogen or is cyano lower alkoxy or is piperidin 2 one or to pharmaceutically active salts sterioisomeric forms including individual diastereoisomers and enantiomers of the compound of formula I as well as racemic and non racemic mixtures thereof..It has been found that the present compounds are high potential NK 3 receptor antagonists for the treatment of depression pain psychosis Parkinsons disease schizophrenia anxiety and attention deficit hyperactivity disorder (ADHD).
